Renalytix

Mount Sinai Health System

Risk stratification and guideline-directed therapy optimization for diabetic kidney disease patients

SGLT2 inhibitor use reached 70% in high-risk patients; 29% of retested patients moved to lower risk category; 43% improvement in eGFR decline rate over 2 years

Wake Forest/Atrium Health

Real-world evidence study for kidney disease risk stratification in type 2 diabetes patients with early-stage CKD

Part of 2,470 patient study showing sustained risk-stratified improvements; combination SGLT2i and GLP-1 RA therapy nearly tripled from 12% to 32%

Clinical validation study cohort

HEDIS metric improvement in high-risk diabetic kidney disease patients

HbA1c levels declined from 8.3 to 7.5%; UACR levels reduced by 10-20%; patients meeting target metrics increased from 33% to 61% at 12-month mark

Mount Sinai

Risk stratification for diabetic kidney disease patients to enable targeted treatment and specialist referrals

High-risk patients 4.5X more likely to be prescribed SGLT2 inhibitors; 2.49X more likely to be referred to specialists

Singing River Health System

Implementation of kidneyintelX.dkd for early-stage diabetic kidney disease management

University of Michigan

Clinical validation and implementation of kidney disease risk stratification using molecular mechanisms and patient data